Ad is loading...
SAGE
Price
$5.10
Change
-$0.27 (-5.03%)
Updated
Nov 15 closing price
94 days until earnings call
TLSA
Price
$0.89
Change
-$0.03 (-3.26%)
Updated
Nov 15 closing price
Ad is loading...

SAGE vs TLSA

Header iconSAGE vs TLSA Comparison
Open Charts SAGE vs TLSABanner chart's image
Sage Therapeutics
Price$5.10
Change-$0.27 (-5.03%)
Volume$1.18M
CapitalizationN/A
Tiziana Life Sciences
Price$0.89
Change-$0.03 (-3.26%)
Volume$104.39K
CapitalizationN/A
SAGE vs TLSA Comparison Chart
Loading...
SAGE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
TLSA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
SAGE vs. TLSA commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SAGE is a Sell and TLSA is a StrongSell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (SAGE: $5.10 vs. TLSA: $0.89)
Brand notoriety: SAGE and TLSA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SAGE: 170% vs. TLSA: 41%
Market capitalization -- SAGE: $311.98M vs. TLSA: $92.45M
SAGE [@Biotechnology] is valued at $311.98M. TLSA’s [@Biotechnology] market capitalization is $92.45M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SAGE’s FA Score shows that 1 FA rating(s) are green whileTLSA’s FA Score has 0 green FA rating(s).

  • SAGE’s FA Score: 1 green, 4 red.
  • TLSA’s FA Score: 0 green, 5 red.
According to our system of comparison, both SAGE and TLSA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SAGE’s TA Score shows that 3 TA indicator(s) are bullish while TLSA’s TA Score has 2 bullish TA indicator(s).

  • SAGE’s TA Score: 3 bullish, 7 bearish.
  • TLSA’s TA Score: 2 bullish, 8 bearish.
According to our system of comparison, SAGE is a better buy in the short-term than TLSA.

Price Growth

SAGE (@Biotechnology) experienced а -19.18% price change this week, while TLSA (@Biotechnology) price change was -4.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

SAGE is expected to report earnings on Feb 19, 2025.

TLSA is expected to report earnings on Dec 28, 2022.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SAGE($312M) has a higher market cap than TLSA($92.5M). TLSA YTD gains are higher at: 59.018 vs. SAGE (-76.465). TLSA has higher annual earnings (EBITDA): -17.14M vs. SAGE (-371.15M). SAGE has more cash in the bank: 569M vs. TLSA (201K). TLSA has less debt than SAGE: TLSA (247K) vs SAGE (10.3M). SAGE has higher revenues than TLSA: SAGE (106M) vs TLSA (0).
SAGETLSASAGE / TLSA
Capitalization312M92.5M337%
EBITDA-371.15M-17.14M2,166%
Gain YTD-76.46559.018-130%
P/E RatioN/AN/A-
Revenue106M0-
Total Cash569M201K283,085%
Total Debt10.3M247K4,170%
FUNDAMENTALS RATINGS
SAGE vs TLSA: Fundamental Ratings
SAGE
TLSA
OUTLOOK RATING
1..100
6393
VALUATION
overvalued / fair valued / undervalued
1..100
23
Undervalued
88
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9597
PRICE GROWTH RATING
1..100
9449
P/E GROWTH RATING
1..100
97100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SAGE's Valuation (23) in the Pharmaceuticals Other industry is somewhat better than the same rating for TLSA (88) in the Biotechnology industry. This means that SAGE’s stock grew somewhat faster than TLSA’s over the last 12 months.

SAGE's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as TLSA (100) in the Biotechnology industry. This means that SAGE’s stock grew similarly to TLSA’s over the last 12 months.

SAGE's SMR Rating (95) in the Pharmaceuticals Other industry is in the same range as TLSA (97) in the Biotechnology industry. This means that SAGE’s stock grew similarly to TLSA’s over the last 12 months.

TLSA's Price Growth Rating (49) in the Biotechnology industry is somewhat better than the same rating for SAGE (94) in the Pharmaceuticals Other industry. This means that TLSA’s stock grew somewhat faster than SAGE’s over the last 12 months.

SAGE's P/E Growth Rating (97) in the Pharmaceuticals Other industry is in the same range as TLSA (100) in the Biotechnology industry. This means that SAGE’s stock grew similarly to TLSA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SAGETLSA
RSI
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
82%
Momentum
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
72%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
77%
Advances
ODDS (%)
Bullish Trend 11 days ago
76%
Bullish Trend 7 days ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Ad is loading...
SAGE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
TLSA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BRZKX11.30-0.07
-0.62%
BlackRock Sus Adg Intl Eq K
MMMPX21.68-0.14
-0.64%
Morgan Stanley Inst Emerging Mkts R6
JCSCX24.46-0.16
-0.65%
Janus Henderson Small Cap Value C
TNVRX18.12-0.18
-0.96%
1290 GAMCO Small/Mid Cap Value R
WMGYX29.55-0.72
-2.38%
Delaware Ivy Mid Cap Growth Y

TLSA and

Correlation & Price change

A.I.dvisor tells us that TLSA and ALLK have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TLSA and ALLK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TLSA
1D Price
Change %
TLSA100%
-3.66%
ALLK - TLSA
26%
Poorly correlated
-1.69%
ADTX - TLSA
24%
Poorly correlated
-7.32%
SAGE - TLSA
24%
Poorly correlated
-5.03%
AGIO - TLSA
23%
Poorly correlated
-2.92%
DARE - TLSA
22%
Poorly correlated
-9.96%
More